China Pharma announced a $5.0 million registered direct offering of 2,500,000 common shares at $2.00 per share under a Securities Purchase Agreement signed on July 22, 2026, with closing expected around July 23, 2026. Terms include a 40% investor participation right in subsequent financings for three months, a 91-day issuance lock-up, and a prohibition on variable-rate transactions for the same period. The company also entered into a Placement Agency Agreement with FT Global Capital, which will receive a 7.0% commission on gross proceeds and an 18-month tail for qualifying future financings. The transactions are intended to bolster liquidity and support corporate needs.
Agreement 1: China Pharma Raises $5 Million in Registered Direct Offering of 2.5M Shares at $2.00
- Agreement type: Securities purchase agreement for registered direct offering of common stock
- Counterparty: Institutional accredited investor
- Signed / Effective: Jul 22 2026 / Jul 22 2026
- Reason: Raise capital and strengthen liquidity
Agreement 2: China Pharma Engages FT Global Capital as Placement Agent With 7% Commission, 18-Month Tail
- Agreement type: Placement agency agreement for registered direct offering
- Counterparty: FT Global Capital
- Signed / Effective: Jul 22 2026 / Jul 22 2026
- Duration / Termination: 18-month tail on future financings
- Reason: Facilitate offering execution and distribution
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.